HMGB1 and steatosis: Recently, for the potential treatment of NASH, J. E. Zhou et al., improved liver function and steatosis in vivo mice through the administration of a mannose-modified HMGB1-siRNA loaded stable nucleic acid lipid particle delivery system for targeting liver macrophages with mannose receptor mediation and thereby silencing HMGB1 [58].